SHARE TEXT
 
E. Jason Abel, MD, FACS close
BiumugHiAAA

E. Jason Abel, MD, FACS Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Abel is board certified by the American Board of Urology and specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers, including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

 

Dr. Abel performs open and laparoscopic surgery, including surgery using the daVinci robot. His philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Specialties

Urology

Bladder Cancer

Cystoscopy

Genitourinary Cancer (Bladder, Kidney, Prostate, Testicular)

Kidney Cancer

Nephrectomy

Prostate Brachytherapy

Prostate Cancer

Prostatectomy

Robotic Cystectomy

Robotic Partial Nephrectomy

Robotic Prostatectomy

Testicular Cancer

Ureteroscopy

Uroflowmetry

Clinics

University Hospital
(608) 263-4757 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Urology

Professional Certifications and Education

Board Certification Urology
Fellowship

Urologic Oncology, M.D. Anderson Cancer Center, Houston, TX


Residency University of Utah Hospital, Salt Lake City, UT
Internship University of Utah Hospital, Salt Lake City, UT
Medical School University of Texas Medical School, Houston, TX

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Abel conducts clinical, translational and basic research in urologic oncology. He currently is involved in several projects focusing on the development and metastasis of kidney cancer.


PubMed Articles
Scrima AT Lubner MG Abel EJ Havighurst TC Shapiro DD Huang W Pickhardt PJ Texture analysis of small renal cell carcinomas at MDCT for predicting relevant histologic and protein biomarkers. Abdom Radiol (NY) . 2019 Jun;44(6):1999-2008
[PubMed ID: 29804215]
Posielski NM Bui A Wells SA Best SL Gettle LM Ziemlewicz TJ Lubner MG Hinshaw JL Lee FT Jr Allen GO Nakada SY Abel EJ Risk Factors for Complications and Nondiagnostic Results following 1,155 Consecutive Percutaneous Core Renal Mass Biopsies. J Urol . 2019 Jun;201(6):1080-1087
[PubMed ID: 30741848]
Best SL Liu Y Keikhosravi A Drifka CR Woo KM Mehta GS Altwegg M Thimm TN Houlihan M Bredfeldt JS Abel EJ Huang W Eliceiri KW Collagen organization of renal cell carcinoma differs between low and high grade tumors. BMC Cancer . 2019 May 23;19(1):490
[PubMed ID: 31122202]
Knott EA Swietlik JF Longo KC Watson RF Green CM Abel EJ Lubner MG Hinshaw JL Smolock AR Xu Z Lee FT Jr Ziemlewicz TJ Robotically-Assisted Sonic Therapy for Renal Ablation in a Live Porcine Model: Initial Preclinical Results. J Vasc Interv Radiol . 2019 May 23;
[PubMed ID: 31130365]
Wang JH Sierra P Richards KA Abel EJ Allen GO Downs TM Jarrard DF Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. BMC Urol . 2019 Apr 23;19(1):26
[PubMed ID: 31014300]
Maciolek KA Abel EJ Posielski NM Hinshaw JL Lubner MG Lee FT Jr Ziemlewicz TJ Wells SA Tumor location does not impact oncologic outcomes for percutaneous microwave ablation of clinical T1a renal cell carcinoma. Eur Radiol . 2019 Apr 23;
[PubMed ID: 31016448]
Jiménez-Torres JA Virumbrales-Muñoz M Sung KE Lee MH Abel EJ Beebe DJ Patient-specific organotypic blood vessels as an in vitro model for anti-angiogenic drug response testing in renal cell carcinoma. EBioMedicine . 2019 Apr;42:408-419
[PubMed ID: 30902740]
Etheridge T Liou JI Downs TM Abel EJ Jarrard DF Richards KA The Impact of Agent Orange Exposure on Prostate Cancer Outcomes. J Urol . 2019 Apr;201(4):742-750
[PubMed ID: 30321553]
Elmaraghi S Chen TJ Heckman JE Shiau JM Williams DH Abel EJ Afifi AM Functional penile replantation after traumatic avulsion amputation below the pubis: A case report. Microsurgery . 2019 Feb 3;
[PubMed ID: 30714225]
Anderson-Carter I Posielski N Liou JI Khemees TA Downs TM Abel EJ Jarrard DF Richards KA The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urol Oncol . 2019 Feb;37(2):130-137
[PubMed ID: 30528885]
Bhindi B Abel EJ Albiges L Bensalah K Boorjian SA Daneshmand S Karam JA Mason RJ Powles T Bex A Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol . 2019 Jan;75(1):111-128
[PubMed ID: 30467042]
Shapiro DD Abel EJ Predicting aggressive behavior in small renal tumors prior to treatment. Ann Transl Med . 2018 Dec;6(Suppl 2):S132
[PubMed ID: 30740453]
Richards KA Liou JI Cryns VL Downs TM Abel EJ Jarrard DF Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol . 2018 Dec;200(6):1256-1263
[PubMed ID: 29940252]
Peyton CC Abel EJ Chipollini J Boulware DC Azizi M Karam JA Margulis V Master VA Matin SF Raman JD Sexton WJ Wood CG Spiess PE The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus . 2018 Sep 8;
[PubMed ID: 30206003]
Maciolek KA Abel EJ Best SL Emamekhoo H Averill SL Ziemlewicz TJ Lubner MG Hinshaw JL Lee FT Jr Wells SA Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. Abdom Radiol (NY) . 2018 Sep;43(9):2446-2454
[PubMed ID: 29464274]
Posielski NM Abel EJ Editorial Comment. J Urol . 2018 Sep;200(3):526-527
[PubMed ID: 29928856]
Maciolek KA Best SL Lopez V Posielski N Knoedler M Bushman WA Jarrard DF Downs TM Abel EJ Richards KA Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urol Oncol . 2018 Aug;36(8):363.e13-363.e20
[PubMed ID: 29887242]
Etheridge T Liou J Downs TM Abel EJ Richards KA Jarrard DF The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy. Am J Clin Exp Urol . 2018;6(3):123-132
[PubMed ID: 30038944]
Hutchinson R Rew C Chen G Woldu S Krabbe LM Meissner M Sheth K Singla N Shakir N Master VA Karam JA Matin SF Borregales LD Wood C Masterson T Thompson RH Boorjian SA Leibovich BC Abel EJ Bagrodia A Margulis V The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology . 2018 May;115:119-124
[PubMed ID: 29499258]
Chipollini J Abel EJ Peyton CC Boulware DC Karam JA Margulis V Master VA Zargar-Shoshtari K Matin SF Sexton WJ Raman JD Wood CG Spiess PE Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer . 2018 Apr;16(2):e443-e450
[PubMed ID: 29113770]